We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+12.19%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.61B
AUM Growth
+$85.8M
Cap. Flow
+$186M
Cap. Flow %
11.54%
Top 10 Hldgs %
76.11%
Holding
34
New
4
Increased
2
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
RPID icon
Rapid Micro Biosystems
RPID
+$174M
2
NUVL
Nuvalent
NUVL
+$99.5M
3
IVVD icon
Invivyd
IVVD
+$92.3M
4
TNGX icon
Tango Therapeutics
TNGX
+$12M
5
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$4.97M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$77.1M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$53.1M
3
DVAX
Dynavax Technologies
DVAX
+$44.6M
4
KYMR icon
Kymera Therapeutics
KYMR
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.57%
2 Financials 2.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$306M 19.01%
4,831,307
-1,000,000
-17% -$77.1M
DVAX
2
DELISTED
Dynavax Technologies
DVAX
$162M 10.03%
8,415,000
-3,356,708
-29% -$44.6M
RPID icon
3
Rapid Micro Biosystems
RPID
$87.2M
$156M 9.66%
+8,434,560
New +$174M
AVIR icon
4
Atea Pharmaceuticals
AVIR
$417M
$130M 8.05%
3,700,000
-1,915,659
-34% -$53.1M
IVVD icon
5
Invivyd
IVVD
$201M
$105M 6.52%
+2,487,207
New +$92.3M
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3.21B
$95.1M 5.9%
3,979,292
– –
NUVL
7
DELISTED
Nuvalent
NUVL
$77.3M 4.8%
+3,428,014
New +$99.5M
CCCC icon
8
C4 Therapeutics
CCCC
$409M
$73.4M 4.55%
1,642,209
– –
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$62.1M 3.85%
3,080,237
– –
ANNX icon
10
Annexon
ANNX
$895M
$60.3M 3.74%
3,241,628
– –
PHVS icon
11
Pharvaris
PHVS
$2.47B
$56.4M 3.5%
3,180,601
– –
NRIX icon
12
Nurix Therapeutics
NRIX
$2.65B
$38.5M 2.39%
1,284,314
– –
CRNX icon
13
Crinetics Pharmaceuticals
CRNX
$8.92B
$35.4M 2.19%
1,679,701
– –
MRSN
14
DELISTED
Mersana Therapeutics
MRSN
$34.9M 2.16%
147,827
– –
SYRS
15
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$25.9M 1.6%
578,504
– –
TNGX icon
16
Tango Therapeutics
TNGX
$4.47B
$24.8M 1.54%
1,921,790
+1,000,000
+108% +$12M
SYRE icon
17
Spyre Therapeutics
SYRE
$9.36B
$22.6M 1.4%
113,908
+5,908
+5% +$1.03M
APTX
18
DELISTED
Aptinyx Inc. Common Stock
APTX
$20.8M 1.29%
8,891,758
– –
SLDB icon
19
Solid Biosciences
SLDB
$911M
$19M 1.18%
528,661
– –
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$16.3M 1.01%
1,431,058
– –
SVRA icon
21
Savara
SVRA
$1.2B
$16M 1%
11,622,598
– –
NAUT icon
22
Nautilus Biotechnolgy
NAUT
$120M
$12.3M 0.76%
2,000,000
– –
XFOR icon
23
X4 Pharmaceuticals
XFOR
$456M
$11.2M 0.7%
70,651
– –
RACB
24
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$9.85M 0.61%
1,000,000
– –
BLUE
25
DELISTED
bluebird bio
BLUE
$7.24M 0.45%
41,547
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2021 Portfolio in Review

As of Q3 2021, Bain Capital Life Sciences Investors held 34 positions worth $1.61B, up 5.6% from $1.53B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Bain Capital Life Sciences Investors deployed $186M of net new capital in Q3 2021, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Rapid Micro Biosystems: 8,434,560 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $77.1M trimmed.

  • Bain Capital Life Sciences Investors's largest Q3 2021 buy was Rapid Micro Biosystems: 8,434,560 shares worth $156M.
  • Bain Capital Life Sciences Investors added most to Tango Therapeutics in Q3 2021, an estimated $12M increase.
  • Bain Capital Life Sciences Investors's biggest Q3 2021 reduction was SpringWorks Therapeutics, cutting an estimated $77.1M.
  • Bain Capital Life Sciences Investors fully exited Kymera Therapeutics in Q3 2021, selling an estimated $23.3M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 76% of its $1.61B portfolio in Q3 2021.
  • Bain Capital Life Sciences Investors opened 4 new positions and closed 1 in Q3 2021.
  • Bain Capital Life Sciences Investors's portfolio value rose 5.6% quarter-over-quarter to $1.61B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2021, filed 15 Nov 2021.